Position in FTRE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,012,779
+$1,050,649 QoQ
Shares Held
115,677
+13.3% QoQ
Ownership
0.122%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#84
of 334 holders
Holding Since
Sep 2023
10 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Creative Planning holds $457,365,908 across 219 Biotechnology names. FTRE ranks #54 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
127,672 | $63,418,511 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,949 | $23,039,178 | |
| 3 | EXEL |
Exelixis, Inc.
|
270,292 | $14,706,586 | |
| 4 | INCY |
Incyte Corp
|
110,664 | $12,544,870 | |
| 5 | CYTK |
Cytokinetics Inc
|
141,939 | $12,091,783 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
64,120 | $12,008,393 | |
| 7 | ARGX |
Argenx SE
|
12,744 | $11,823,500 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
153,161 | $8,763,872 |
All Filings in FTRE
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,012,779 | 115,677 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $962,130 | 102,137 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $1,515,498 | 87,855 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $645,493 | 76,662 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $249,247 | 50,455 | Shares | Defined | 2025-08-08 | |
| 2025-03-31 | $76,292 | 10,105 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $167 | 9 | Shares | Defined | 2025-02-14 | |
| 2024-03-31 | $317,146 | 7,901 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $281,957 | 8,079 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $229,034 | 8,011 | Shares | Sole | 2023-11-16 | |
| No filing history on record for this holder in this stock. | ||||||